Summit Therapeutics Inc. $(SMMT)$ has announced the issuance of inducement awards consisting of options to purchase up to 94,050 shares of common stock. These awards have been granted to nine new employees as part of their employment agreement with the company, in accordance with Nasdaq Listing Rule 5635(c)(4). Approved by the Company's Compensation Committee, the options have a ten-year term and an exercise price of $22.75 per share, reflecting the closing price on May 14, 2025. The options will vest in equal annual installments over four years and are subject to a stock option agreement to be signed by each recipient.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。